Cancer of unknown primary (CUP) is rare, accounting for up to 1% of all breast cancers. 1 We refer to the term "CUP syndrome" when cancer cells have spread and metastasized in the body but the primary site of cancer is unknown and/or cannot be identified. 2 Breast cancer may be especially suspected when axillary nodes are involved, but mammography and ultrasound are often negative. Breast MRI is recommended by international guidelines in case of findings suspicious for CUP syndrome 1,3 which enables the detection of an occult primary breast cancer in 35-100% of cases. If breast MRI is negative, immediate surgery may be avoided. 1,3
The patient demonstrated an increase in blood markers, namely CA 15.3 (125 UI/ml), CA 125 (272 UI/ml), CEA (32 ng ml −1 ), but at colonoscopy, mammography and breast ultrasound no significant findings were found with the exception of multiple enlarged and suspicious bilateral axillary lymph nodes (Figure 1 ).
Contrast-enhanced body-CT scan was undertaken and revealed multiple suspicious lymph nodes in several mediastinal and abdominal lymphatic stations ( Figure 2 ). Furthermore, it confirmed numerous enlarged nodes in both axilla, with a prominent suspicious node in the left side (20 mm). To better define these CT findings, a PET/CT scan was performed. PET/CT showed high metabolic activity of the lymphadenopathies especially in the left axilla (SUV ranged between 7.41 and 9.10) with a significant uptake of the enlarged 20 mm node of the left axilla ( Figure 3 ). Therefore, a biopsy of the left axillary node was performed with the final result of cancer cells of breast origin (ER 95%, PGR 5%, Her 3+, Mib-1 5%). Therefore, following the International recommendations, 1,3 we performed a breast MRI that showed a focal non-mass lesion of about 9 mm in the inner-medial region of the right breast (BI-RADS 4) and the bilateral axillary lymphadenopathies ( Figure 4 ). No correlation was found at a second-look ultrasound. The patient started first-line treatment with docetaxel + trastuzumab and pertuzumab. A new breast MRI was performed at the end of the third cycle of treatment ( Figure 5 ). The lesion was stable lesion in size with a decrease in enhancement. Therefore, the patient underwent to a breast MRI biopsy in another facility with the pathological diagnosis of usual ductal hyperplasia which was confirmed at the final histological evaluation.
disCUssion
Up to 4% of newly diagnosed cases of malignant neoplasms involve CUP, representing the fourth most common cause of cancer death in both males and females. Usually, the first manifestations of CUP consist in metastases to lymph nodes, lungs, liver or bones and the primary tumor can be detected in up to 40% of patients. CUP syndrome still have a poor prognosis, with a median of 2 year survival in patients with disseminated disease. 4 CUP syndrome includes a multitude of possible differential diagnosis, such as lymphoma, melanoma and lung cancer. 5 
